Insider Selling: OmniAb, Inc. (NASDAQ:OABI) Insider Sells 25,489 Shares of Stock

OmniAb, Inc. (NASDAQ:OABI - Get Free Report) insider Charles S. Berkman sold 25,489 shares of OmniAb stock in a transaction dated Tuesday, January 21st. The stock was sold at an average price of $3.24, for a total value of $82,584.36. Following the completion of the sale, the insider now owns 343,190 shares in the company, valued at approximately $1,111,935.60. The trade was a 6.91 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink.

OmniAb Stock Down 0.6 %

Shares of OABI traded down $0.02 during trading on Wednesday, reaching $3.20. 576,116 shares of the company traded hands, compared to its average volume of 413,324. The stock has a 50-day simple moving average of $3.69 and a 200-day simple moving average of $4.07. The stock has a market cap of $451.90 million, a PE ratio of -5.16 and a beta of -0.10. OmniAb, Inc. has a twelve month low of $3.16 and a twelve month high of $6.55.

Institutional Trading of OmniAb

A number of institutional investors and hedge funds have recently added to or reduced their stakes in OABI. Murchinson Ltd. acquired a new stake in shares of OmniAb in the third quarter valued at $4,230,000. Dimensional Fund Advisors LP grew its position in OmniAb by 6.9% in the 2nd quarter. Dimensional Fund Advisors LP now owns 3,012,216 shares of the company's stock valued at $11,296,000 after acquiring an additional 194,835 shares in the last quarter. Rice Hall James & Associates LLC increased its stake in OmniAb by 6.4% during the third quarter. Rice Hall James & Associates LLC now owns 2,722,321 shares of the company's stock worth $11,515,000 after purchasing an additional 163,038 shares during the period. Squarepoint Ops LLC acquired a new stake in shares of OmniAb during the second quarter worth about $449,000. Finally, Barclays PLC boosted its stake in shares of OmniAb by 321.5% in the third quarter. Barclays PLC now owns 143,215 shares of the company's stock valued at $606,000 after purchasing an additional 109,236 shares during the period. Hedge funds and other institutional investors own 72.08% of the company's stock.

Analysts Set New Price Targets

OABI has been the subject of several research reports. HC Wainwright reaffirmed a "buy" rating and set a $11.00 price objective on shares of OmniAb in a research note on Thursday, November 14th. Benchmark reaffirmed a "buy" rating and issued a $8.00 price target on shares of OmniAb in a report on Thursday, November 14th.

About OmniAb

OmniAb, Inc, a biotechnology company, engages in the discovery and provision of therapeutic antibody discovery technologies in the United States. The company's technology platform creates and screens diverse antibody repertoires and identify optimal antibodies for partners' drug development efforts.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.